Ondansetron Tablets USP 8 mg + Ondansetron Hydrochloride
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout Ondansetron Tablets USP 8 mg + Ondansetron Hydrochloride
Ondansetron Tablets USP 8 mg + Ondansetron Hydrochloride is a phase 1 stage product being developed by Ipca Laboratories for Fed. The current trial status is completed. This product is registered under clinical trial identifier NCT01578265. Target conditions include Fed.
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01578252 | Phase 1 | Completed |
| NCT01578265 | Phase 1 | Completed |
Competing Products
20 competing products in Fed